Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 4217

1.
3.

Histology of prophylactically removed ovaries from BRCA1 and BRCA2 mutation carriers compared with noncarriers in hereditary breast ovarian cancer syndrome kindreds.

Casey MJ, Bewtra C, Hoehne LL, Tatpati AD, Lynch HT, Watson P.

Gynecol Oncol. 2000 Sep;78(3 Pt 1):278-87. Review.

PMID:
10985881
4.

Peritoneal carcinoma in women with genetic susceptibility: implications for Jewish populations.

Casey MJ, Bewtra C.

Fam Cancer. 2004;3(3-4):265-81. Review.

PMID:
15516851
5.
6.

Breast and ovarian cancer risk perception after prophylactic salpingo-oophorectomy due to an inherited mutation in the BRCA1 or BRCA2 gene.

Finch A, Metcalfe K, Lui J, Springate C, Demsky R, Armel S, Rosen B, Murphy J, Elit L, Sun P, Narod S.

Clin Genet. 2009 Mar;75(3):220-4.

PMID:
19263514
7.

Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations.

Rebbeck TR, Lynch HT, Neuhausen SL, Narod SA, Van't Veer L, Garber JE, Evans G, Isaacs C, Daly MB, Matloff E, Olopade OI, Weber BL; Prevention and Observation of Surgical End Points Study Group.

N Engl J Med. 2002 May 23;346(21):1616-22. Epub 2002 May 20.

8.

Pathologic findings in prophylactic oophorectomy specimens in high-risk women.

Leeper K, Garcia R, Swisher E, Goff B, Greer B, Paley P.

Gynecol Oncol. 2002 Oct;87(1):52-6.

PMID:
12468342
9.

Gynecologic surgeries and risk of ovarian cancer in women with BRCA1 and BRCA2 Ashkenazi founder mutations: an Israeli population-based case-control study.

Rutter JL, Wacholder S, Chetrit A, Lubin F, Menczer J, Ebbers S, Tucker MA, Struewing JP, Hartge P.

J Natl Cancer Inst. 2003 Jul 16;95(14):1072-8.

PMID:
12865453
10.

Clinical outcome of prophylactic oophorectomy in BRCA1/BRCA2 mutation carriers and events during follow-up.

Olivier RI, van Beurden M, Lubsen MA, Rookus MA, Mooij TM, van de Vijver MJ, van't Veer LJ.

Br J Cancer. 2004 Apr 19;90(8):1492-7.

11.

Use of genetic testing and prophylactic mastectomy and oophorectomy in women with breast or ovarian cancer from families with a BRCA1 or BRCA2 mutation.

Meijers-Heijboer H, Brekelmans CT, Menke-Pluymers M, Seynaeve C, Baalbergen A, Burger C, Crepin E, van den Ouweland AW, van Geel B, Klijn JG.

J Clin Oncol. 2003 May 1;21(9):1675-81.

PMID:
12721241
12.

Prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers.

Rebbeck TR.

J Clin Oncol. 2000 Nov 1;18(21 Suppl):100S-3S. Review.

PMID:
11060335
13.

Breast cancer risk after bilateral prophylactic oophorectomy in BRCA1 mutation carriers.

Rebbeck TR, Levin AM, Eisen A, Snyder C, Watson P, Cannon-Albright L, Isaacs C, Olopade O, Garber JE, Godwin AK, Daly MB, Narod SA, Neuhausen SL, Lynch HT, Weber BL.

J Natl Cancer Inst. 1999 Sep 1;91(17):1475-9.

PMID:
10469748
14.

Clinical experience of prophylactic mastectomy followed by immediate breast reconstruction in women at hereditary risk of breast cancer (HB(O)C) or a proven BRCA1 and BRCA2 germ-line mutation.

Contant CM, Menke-Pluijmers MB, Seynaeve C, Meijers-Heijboer EJ, Klijn JG, Verhoog LC, Tjong Joe Wai R, Eggermont AM, van Geel AN.

Eur J Surg Oncol. 2002 Sep;28(6):627-32.

PMID:
12359199
15.

Association between clinical characteristics and risk-reduction interventions in women who underwent BRCA1 and BRCA2 testing: a single-institution study.

Uyei A, Peterson SK, Erlichman J, Broglio K, Yekell S, Schmeler K, Lu K, Meric-Bernstam F, Amos C, Strong L, Arun B.

Cancer. 2006 Dec 15;107(12):2745-51.

16.

Hereditary ovarian cancer.

Prat J, Ribé A, Gallardo A.

Hum Pathol. 2005 Aug;36(8):861-70. Review.

PMID:
16112002
17.

The average cumulative risks of breast and ovarian cancer for carriers of mutations in BRCA1 and BRCA2 attending genetic counseling units in Spain.

Milne RL, Osorio A, Cajal TR, Vega A, Llort G, de la Hoya M, Díez O, Alonso MC, Lazaro C, Blanco I, Sánchez-de-Abajo A, Caldés T, Blanco A, Graña B, Durán M, Velasco E, Chirivella I, Cardeñosa EE, Tejada MI, Beristain E, Miramar MD, Calvo MT, Martínez E, Guillén C, Salazar R, San Román C, Antoniou AC, Urioste M, Benítez J.

Clin Cancer Res. 2008 May 1;14(9):2861-9. doi: 10.1158/1078-0432.CCR-07-4436.

18.

Breast cancer and ovarian cancer genetics.

Edlich RF, Winters KL, Lin KY.

J Long Term Eff Med Implants. 2005;15(5):533-45. Review.

PMID:
16218901
19.

Prevention and therapy for BRCA1/2 mutation carriers and women at high risk for breast and ovarian cancer.

Kuschel B, Lux MP, Goecke TO, Beckmann MW.

Eur J Cancer Prev. 2000 Jun;9(3):139-50. Review.

PMID:
10954253
20.

Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group.

Rebbeck TR, Friebel T, Lynch HT, Neuhausen SL, van 't Veer L, Garber JE, Evans GR, Narod SA, Isaacs C, Matloff E, Daly MB, Olopade OI, Weber BL.

J Clin Oncol. 2004 Mar 15;22(6):1055-62. Epub 2004 Feb 23.

PMID:
14981104

Supplemental Content

Support Center